Home › Forums › General Discussion › General Discussion › Establishing iPSCs under GMP conditions › Reply To: Establishing iPSCs under GMP conditions
Last year we launched the first commercial reprogramming kit, “CTS CytoTune iPS 2.1 Sendai Reprogramming Kit” specifically designed for clinical and translational use.
Our workflow approach to product development also means that compatible media and characterization solutions are integrated including our new CTS Essential 8 media and scalable molecular characterization tools, PluriTest, Scorecard and KaryoStat to confirm pluripotency and karyotypic stability.
These CTS products provides an efficient regulatory pathway to transition from research to translational research with confidence. In addition to being manufactured according the GMP principles, these products come with regulatory expert support, extensive testing and traceablility documentation including Certificates of Analysis, Certificates of Origin and Drug Master Files.
Please do let me know if I can provide any additional information.